Bisphosphonates
Drugs - Bisphosphonates
December 2012
Therapeutic area - Osteoporosis
PDL Status
Musculoskeletal/Osteoporosis
Bisphosphonates
Preferred |
Nonpreferred |
alendronate |
Actonel/ibandronate PA
Atelvia (risedronate) PA
Binosto PA
Boniva tablets and injectable PA
Fosamax PA
Fosamax Plus D |
Approval criteria
Actonel, branded Fosamax or Boniva/ibandronate tablets
- Patient has had intolerable side effects from alendronate (Fosamax) after having been instructed to stand or sit upright for at least 30 minutes
- If patient is to receive Boniva or ibandronate, patient must be informed to stand or sit upright for at least 60 minutes after taking it
Atelvia
- Patient must have tried and failed by intolerance BOTH alendronate generic and Actonel AND
- Prescriber must provide rationale why new formulation of risedronate in Atelvia will provide better results
Bonisto
- Patient must have tried and failed alendronate, ibandronate and Actonel OR
- Intolerance to alendrondate, ibandronate or Actonel, defined as moderate or severe upper GI tract irritation due to the tablet formulation OR
- Diagnoses of dysphagia
Boniva Infusion
- Boniva infusion is approved for use only after the prescriber or pharmacy provides a reasonable explanation of why the patient cannot take a bisphosphonate by mouth (e.g., Roux-en-Y Bariatric Surgery)
Questions?
MHCP Provider Call Center 651-431-2700 or 800-366-5411